日本の自己免疫疾患診断市場規模、成長と動向分析レポート 2025-2033年

日本の自己免疫疾患診断市場 – 検査（全身性自己免疫疾患診断、局所性自己免疫疾患診断）、製品別、検査タイプ別、最終用途別、およびセグメント別予測による市場規模、成長と動向分析レポート 2025-2033年

日本の自己免疫疾患診断市場規模は、2024年に3億6,549万米ドルと推定され、2033年には6億4,045万米ドルに達すると予測されています。2025年から2033年にかけて年平均成長率（CAGR）6.6%で成長します。人口の29%以上が65歳以上と世界で最も急速に高齢化が進む日本は、関節リウマチや自己免疫性膵炎などの疾患の有病率上昇に直面しています。このことが、ANA検査、自己抗体パネル、高度な分子アッセイの需要を高めています。この成長は、マルチプレックス免疫測定、AI、バイオマーカー発見におけるイノベーション、そして産学連携の強化によってさらに支えられています。シスメックス、MBL、Autobio Diagnosticsなどのパートナーシップは、精度、拡張性、そして疾患の早期発見を向上させます。

総務省統計局（2023年10月）によると、日本の人口は1億2,435万人で、前年比59万5,000人（-0.48%）減少し、13年連続の減少となりました。男性人口は6,049万人（-0.44%）、女性人口は6,386万人（-0.51%）と、それぞれ減少しました。人口の自然減は、男性で19年、女性で15年続いており、人口減少が続いています。しかしながら、人口純増の傾向がこれをある程度補っており、日本人の人口純増は3年ぶりにプラスに転じ、外国人住民人口も着実に増加しています。

本レポートでは、2021年から2033年までの各サブセグメントの収益成長を予測し、最新の動向を分析しています。グランドビューリサーチは、本レポートのために、日本の自己免疫疾患診断市場をタイプ、製品、検査タイプ、最終用途に基づいてセグメント化しました。

Market Size & Trends

The Japan autoimmune disease diagnostics market size was estimated at USD 365.49 million in 2024 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world’s fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.

According to the Statistics Bureau of Japan (October 2023), the country’s population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.

This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.

Japan Autoimmune Disease Diagnostics Market Report Scope

Japan Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:

• Type Outlook (Revenue, USD Million, 2021 – 2033)
• Systemic autoimmune disease diagnostics

o Rheumatoid arthritis

o Ankylosing spondylitis diagnostics

o Systemic lupus erythematosus (SLE)

o Others

• Localized autoimmune disease diagnostics

o Multiple sclerosis

o Type 1 diabetes

o Hashimoto’s Thyroiditis

o Idiopathic thrombocytopenic purpura

o Others

• Product Outlook (Revenue, USD Million, 2021 – 2033)
• Instruments
• Consumables & Assays
• Test Type Outlook (Revenue, USD Million, 2021 – 2033)
• Antinuclear antibody tests

o Indirect Immunofluorescence (IIF) ANA tests

o ELISA-based ANA tests

o Multiplex/line immunoassay ANA panels

o Others

• Autoantibody tests

o Rheumatoid Factor (RF) tests

o Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests

o Anti-dsDNA tests

o Anti-Smith (Sm) antibody tests

o Anti-Ro/SSA & Anti-La/SSB antibody tests

o Others

• C-reactive Protein (CRP)
• Complete blood count (CBC)
• Urinalysis
• Others
• End Use Outlook (Revenue, USD Million, 2021 – 2033)
• Hospitals
• Diagnostic Centers
• Others

Table of Contents

Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope

1.1. Market Segmentation and Scope

1.1.1. Segment Definitions

1.1.1.1. Type Segment

1.1.1.2. Technology Segment

1.1.1.3. End Use Segment

1.2. Estimates and Forecast Timeline

1.3. Objectives

1.3.1. Objective – 1

1.3.2. Objective – 2

1.3.3. Objective – 3

1.4. Research Methodology

1.5. Information Procurement

1.5.1. Purchased Database

1.5.2. GVR’s Internal Database

1.5.3. Secondary Sources

1.5.4. Primary Research

1.6. Information or Data Analysis

1.6.1. Data Analysis Models

1.7. Market Formulation & Validation

1.8. Model Details

1.8.1. Commodity Flow Analysis

1.9. List of Secondary Sources

1.10. List of Abbreviations

Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary

2.1. Market Snapshot

2.2. Type and Product Snapshot

2.3. Test Type and End Use Snapshot

2.4. Competitive Landscape Snapshot

Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope

3.2. Market Lineage Outlook

3.2.1. Parent Market Outlook

3.2.2. Related/Ancillary Market Outlook

3.3. Market Dynamics

3.4. Market Drivers Analysis

3.4.1. Rising demand for early and non-invasive diagnosis

3.4.2. Technological advancements

3.4.3. Academic-industry collaborations

3.5. Market Restraint Analysis

3.5.1. High cost and limited reimbursement coverage

3.6. Market Opportunity Analysis

3.6.1. Expansion of personalized medicine and biomarker-based testing

3.7. Porter’s Five Forces Analysis

3.8. PESTLE Analysis

Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis

4.2. Systemic autoimmune disease diagnostics

4.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.2.2. Rheumatoid arthritis

4.2.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.2.3. Ankylosing spondylitis diagnostics

4.2.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.2.4. Systemic lupus erythematosus (SLE)

4.2.4.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.2.5. Others

4.2.5.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3. Localized autoimmune disease diagnostics

4.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3.2. Multiple sclerosis

4.3.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3.3. Type 1 diabetes

4.3.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3.4. Hashimoto’s Thyroiditis

4.3.4.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3.5. Idiopathic thrombocytopenic purpura

4.3.5.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

4.3.6. Others

4.3.6.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis

5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis

5.2. Instruments

5.2.1. Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)

5.3. Consumables & Assays

5.3.1. Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)

5.4. Mass spectrometry-based assays

Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis

6.2. Antinuclear antibody tests

6.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.2.2. Indirect Immunofluorescence (IIF) ANA tests

6.2.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.2.3. ELISA-based ANA tests

6.2.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.2.4. Multiplex/line immunoassay ANA panels

6.2.4.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.2.5. Others

6.2.5.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3. Autoantibody tests

6.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.2. Rheumatoid Factor (RF) tests

6.3.2.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests

6.3.3.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.4. Anti-dsDNA tests

6.3.4.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.5. Anti-Smith (Sm) antibody tests

6.3.5.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests

6.3.6.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.3.7. Others

6.3.7.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.4. C-reactive Protein (CRP)

6.4.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.5. Complete blood count (CBC)

6.5.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.6. Urinalysis

6.6.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

6.7. Others

6.7.1. Market Estimates and Forecasts, 2021 – 2033 (USD Million)

Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis

7.2. Hospitals

7.2.1. Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)

7.3. Diagnostic Centers

7.3.1. Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)

7.4. Others

7.4.1. Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization

8.2. Strategy Mapping

8.2.1. NEW PRODUCT LAUNCH

8.2.2. PARTNERSHIPS

8.2.3. ACQUISITION

8.2.4. COLLABORATION

8.2.5. FUNDING

8.3. Key Company Market Share Analysis, 2024

8.4. Company Heat Map Analysis

8.5. Company Profiles

8.5.1. Fujirebio

8.5.2. SEKISUI MEDICAL CO., LTD

8.5.2.1. Company Overview

8.5.2.2. Financial Performance

8.5.2.3. Product Benchmarking

8.5.2.4. Strategic Initiatives

8.5.3. Medical & Biological Laboratories (MBL)

8.5.3.1. Company Overview

8.5.3.2. Financial Performance

8.5.3.3. Product Benchmarking

8.5.3.4. Strategic Initiatives

8.5.4. Bio-Rad Laboratories, Inc.

8.5.4.1. Company Overview

8.5.4.2. Financial Performance

8.5.4.3. Product Benchmarking

8.5.4.4. Strategic Initiatives

8.5.5. Abbott

8.5.5.1. Company Overview

8.5.5.2. Financial Performance

8.5.5.3. Product Benchmarking

8.5.5.4. Strategic Initiatives

8.5.6. F. Hoffmann-La Roche, Ltd.

8.5.6.1. Overview

8.5.6.2. Financial Performance

8.5.6.3. Product Benchmarking

8.5.6.4. Strategic Initiatives

8.5.7. Siemens Healthineers AG

8.5.7.1. Company Overview

8.5.7.2. Financial Performance

8.5.7.3. Product Benchmarking

8.5.7.4. Strategic Initiatives

8.5.8. Sysmex Corporation

8.5.8.1. Grifols Company Overview

8.5.8.2. Financial Performance

8.5.8.3. Product Benchmarking

8.5.8.4. Strategic Initiatives

8.5.9. BioMérieux

8.5.9.1. Company Overview

8.5.9.2. Financial Performance

8.5.9.3. Product Benchmarking

8.5.9.4. Strategic Initiatives

8.5.10. Beckman Coulter ( Danaher)

8.5.10.1. Company Overview

8.5.10.2. Financial Performance

8.5.10.3. Product Benchmarking

8.5.10.4. Strategic Initiatives

List of Tables

Table 1 List 0f Abbreviation

Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 – 2033 (USD Million)

Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 – 2033 (USD Million)

Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 – 2033 (USD Million)

Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 – 2033 (USD Million)

List of Figures

Fig. 1 Market research process

Fig. 2 Information procurement

Fig. 3 Market summary

Fig. 4 Market segmentation & scope

Fig. 5 Market size and growth prospects

Fig. 6 Japan autoimmune disease diagnostics market – Key market driver analysis

Fig. 7 Japan autoimmune disease diagnostics market – Key market restraint analysis

Fig. 8 Penetration & growth prospect mapping

Fig. 9 Japan autoimmune disease diagnostics market – Porter’s analysis

Fig. 10 Japan autoimmune disease diagnostics market – PESTEL analysis

Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways

Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis

Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 – 2033 (USD Million)

Fig. 14 Rheumatoid arthritis market estimates, 2021 – 2033 (USD Million)

Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 – 2033 (USD Million)

Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 – 2033 (USD Million)

Fig. 17 Multiple sclerosis market estimates, 2021 – 2033 (USD Million)

Fig. 18 Type 1 diabetes market estimates, 2021 – 2033 (USD Million)

Fig. 19 Hashimoto’s Thyroiditis market estimates, 2021 – 2033 (USD Million)

Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 – 2033 (USD Million)

Fig. 21 Others market estimates, 2021 – 2033 (USD Million)

Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways

Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis

Fig. 24 Instruments market estimates, 2021 – 2033 (USD Million)

Fig. 25 Consumables & Assays market estimates, 2021 – 2033 (USD Million)

Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways

Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis

Fig. 28 Antinuclear antibody tests market estimates, 2021 – 2033 (USD Million)

Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 – 2033 (USD Million)

Fig. 30 ELISA-based ANA tests market estimates, 2021 – 2033 (USD Million)

Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 – 2033 (USD Million)

Fig. 32 Others market estimates, 2021 – 2033 (USD Million)

Fig. 33 Autoantibody tests market estimates, 2021 – 2033 (USD Million)

Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 – 2033 (USD Million)

Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 – 2033 (USD Million)

Fig. 36 Anti-dsDNA tests estimates, 2021 – 2033 (USD Million)

Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 – 2033 (USD Million)

Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 – 2033 (USD Million)

Fig. 39 Others estimates, 2021 – 2033 (USD Million)

Fig. 40 C-reactive Protein (CRP) market estimates, 2021 – 2033 (USD Million)

Fig. 41 Complete blood count (CBC) market estimates, 2021 – 2033 (USD Million)

Fig. 42 Urinalysis market estimates, 2021 – 2033 (USD Million)

Fig. 43 Others market estimates, 2021 – 2033 (USD Million)

Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways

Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis

Fig. 46 Hospitals market estimates, 2021 – 2033 (USD Million)

Fig. 47 Diagnostic Centers market estimates, 2021 – 2033 (USD Million)

Fig. 48 Others market estimates, 2021 – 2033 (USD Million)

Fig. 49 Strategy framework

Grand View Researchについて

Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ 1

ライセンスタイプ 2

ライセンスタイプ 3

ライセンスタイプ 4

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（インディビジュアルライセンス）
    • 1名のみレポートファイル（印刷不可）をご利用いただけます。
  • チームライセンス
    • 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
  • コーポレートライセンス
    • 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
    • 「関連会社」の範囲についてはお気軽にお問い合わせください。
• 納品形態
  • オンラインダウンロード
• 納期
  • ご注文後1～7営業日　※レポートにより異なります。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新出版レポート

• イーサネット測定機器市場規模、成長と動向分析レポート 2025-2033年
• AIビデオ分析市場規模、成長と動向分析レポート 2025-2033年
• イベントマネジメント市場規模、成長と動向分析レポート 2025-2033年
• IPTVソフトウェア市場規模、成長と動向分析レポート 2025-2033年
• スマートホームセキュリティカメラ市場規模、成長と動向分析レポート 2025-2033年

出版レポート一覧